ZH9 + Checkpoint Inhibitors
Muscle-Invasive Bladder Cancer (MIBC)
Discovery/PreclinicalActive
Key Facts
Indication
Muscle-Invasive Bladder Cancer (MIBC)
Phase
Discovery/Preclinical
Status
Active
Company
About Prokarium
Prokarium is a UK-based biotech developing a novel class of off-the-shelf, programmable bacterial immunotherapies for cancer. Its foundational technology centers on a proprietary Salmonella ZH9 strain, engineered to be naturally tumor-targeting and oncolytic, serving as a delivery platform for therapeutic payloads. The company has a lead clinical-stage asset for non-muscle invasive bladder cancer (NMIBC) and is developing an oral 'IO Prime' agent to boost responses to other immunotherapies. Backed by experienced leadership and investors like Flerie Invest, Prokarium aims to address significant unmet needs in oncology with its synthetic biology-driven Living Cures platform.
View full company profileTherapeutic Areas
Other Muscle-Invasive Bladder Cancer (MIBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Cretostimogene + Nivolumab | CG Oncology | Phase 2 |
| NDV-01 | Relmada Therapeutics | Pre-Clinical / Phase 2 Planned |